SABS
SAB Biotherapeutics, Inc.
+0.10 (+3.10%)3.50USD119K成交股數318M市值15.2本益比(近四季)–股價營收比–營收年增(近四季)2026-11-12下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | – | – | – | – | – | – | – | 263K-55% | 945K | 1.3M | 86K | 581K |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 16.2M | 13.4M | 9.0M | 7.0M | 7.7M | 7.5M | 7.8M | 6.8M | 8.1M | 4.0M | 3.7M | 4.5M |
| 銷售管理費用 | 7.2M | 6.6M | 3.7M | 2.7M | 3.1M | 2.7M | 3.5M | 3.6M | 4.2M | 2.6M | 2.9M | 3.4M |
| 營業利益 | −23.4M+117% | −20.0M+100% | −12.7M+12% | −9.7M-5% | −10.8M-5% | −10.0M+88% | −11.3M+75% | −10.2M+38% | −11.4M | −5.3M | −6.5M | −7.4M |
| 營業利益率 | – | – | – | – | – | – | – | -3,877.0% | -1,205.9% | -420.0% | -7,573.4% | -1,273.8% |
| 稅後淨利 | −22.5M+333% | −18.9M+66% | 45.4M-539% | −10.1M+38% | −5.2M+3% | −11.4M+123% | −10.3M+50% | −7.3M-0% | −5.0M | −5.1M | −6.9M | −7.4M |
| 淨利率 | – | – | – | – | – | – | – | -2,787.7% | -532.1% | -402.6% | -8,046.1% | -1,265.5% |
| 稀釋 EPS | -0.28-50% | -0.35-72% | -0.21-81% | -1.09+38% | -0.56+4% | -1.23+27% | -1.12-18% | -0.79-46% | -0.54 | -0.97 | -1.36 | -1.46 |
| 稀釋股數 | 79.8M | 53.6M | 77.9M | 9.3M | 9.3M | 9.3M | 9.3M | 9.3M | 9.2M | 5.2M | 5.0M | 5.0M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 8.3M | 20.5M | 29.4M | 3.7M | 5.6M | 8.9M | 9.2M | 17.2M | 14.0M | 2.4M | 7.8M | 13.1M |
| 應收帳款 | – | – | – | – | – | – | – | – | – | 0.00 | 364K | 763K |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 238M | 248M | 183M | 30.1M | 38.1M | 44.2M | 53.8M | 61.9M | 71.4M | 28.3M | 35.4M | 42.7M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 23.4M | 21.2M | 18.4M | 18.1M | 16.7M | 18.2M | 16.9M | 15.8M | 18.5M | 13.1M | 15.7M | 18.3M |
| 股東權益 | 215M | 227M | 165M | 12.0M | 21.4M | 26.0M | 36.9M | 46.1M | 52.8M | 15.3M | 19.7M | 24.4M |
| 負債比 | 9.8% | 8.5% | 10.0% | 60.1% | 43.8% | 41.2% | 31.4% | 25.5% | 26.0% | 46.2% | 44.4% | 42.8% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −14.3M | – | – | −7.8M-27% | – | – | – | −10.8M | – | – | −1.6M |
| 資本支出 | – | 983K | – | – | – | – | – | – | 129K | – | – | 21K |
| 自由現金流 | – | −15.3M | – | – | – | – | – | – | −10.9M | – | – | −1.6M |
| 折舊攤銷 | 800K | 731K | 700K | 800K | 757K | 843K | 900K | 1.0M | 2.0M | 1.0M | 900K | 898K |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | – | – | – | – | – | – | -1,151.7% | – | – | -280.0% |
營收拆解 2022 年度 10-K 的分部揭露 · 年增對前一年度
產品／服務2022 年度 · 23.9M
| Grant | 23.9M | 100.0% | -60.7% |
|---|
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 0.00 | -100.0% | 13.3M | –% | -0.79 | −45.7M |
| FY2024 | 1.3M | -40.9% | −34.1M | -2,579.0% | -3.68 | −34.6M |
| FY2023 | 2.2M | -90.6% | −42.2M | -1,884.5% | -7.64 | −25.3M |
| FY2022 | 23.9M | -60.7% | −18.7M | -78.4% | -4.31 | −25.6M |
| FY2021 | 60.9M | +10.2% | −17.1M | -28.2% | -0.63 | −9.0M |
| FY2020 | 55.2M | – | 20.1M | 36.4% | 0.74 | −2.7M |